Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Terapia con células dendríticas para perros, gatos y caballos

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20160714001
Publicado:
19/07/2016
Caducidad:
19/07/2017
Resumen:
Una pyme alemana ofrece una terapia de células dendríticas (terapia CD) como nuevo tratamiento contra el cáncer en medicina veterinaria (perros, gatos y caballos). Las células del cuerpo del paciente son procesadas con el fin de fabricar productos individuales para el tratamiento. Posteriormente estas células son enviadas al veterinario para su aplicación. La empresa busca centros veterinarios, clínicas y asociaciones veterinarias en Reino Unido, Austria, España, Singapur y Estados Unidos, aunque también tendrá en cuenta otros países, para instaurar esta terapia mediante diferentes tipos de acuerdos.

Details

Tittle:
Dendritic cell therapy for dogs, cats and horses
Summary:
A German SME offers dendritic cell therapy (DC therapy) as a new and innovative cancer treatment in veterinary medicine (dogs, cats and horses). The SME is looking for partners from veterinary centers, clinics and practices as well as contact to veterinary associations mainly in the UK but also from Austria, Spain, Singapore and USA to further establish this therapy approach under various kinds of possible agreements. Partners from other countries may be considered.
Description:
The German SME was founded in 2012 and established a GMP manufacture site for the dendritic cell therapy in the veterianry field. The companies first product is - compared to standard treatments today - a safer and superior cancer treatment for dogs, cats, and horses.

The SME is a combination of a lab and a traditional pharmaceutical manufacturer. Cells from the patient´s own body are used and processed to manufacture individual products for the treatment. Afterwards these cells are brought back to the veterinarian for application.

Dendric cell therapy treatment is either used adjuvant to surgery (complete or partial excision) or as a palliative treatment without surgery. If used in combination with surgery, remaining tumor tissue is destroyed and recurrence prevented. Without surgery, progression is stopped, possibly getting the tumor into re-mission and improving the quality of life of the patient. Furthermore the therapy can regenerate organ functions in these species (similar to the benefits of stem cell treatments).

The German SME expects that more high-end treatments (similar to treatments seen in human science) will be adapted to veterinary science as patients become older and often are a full member of the family.
Especially interesting market is the UK as 25% of dogs are covered by health insurances. In the past, health insurances in the UK have covered the cost of the companies treatments.

The German SME is interested to gain contacts to veterinary centers, clinics and practices as well as contact to veterinary associations mainly in the UK but also from Austria, Spain, Singapore and the USA to further establish this therapy approach under various kinds of possible agreements like:
- Commercial agreement with technical asstistance
- Service agreement

Also a Joint venture agreement could be possible to expand the lab facilities to UK.

Furthermore the company is interested in research collaborations to further develop the technology to other treatment areas such as autoimmune diseases and regenerative applications.

Partners from other countries may be considered.
Advantages and Innovations:
- In comparison to other tumor therapies, the SME provide an individualized therapy for the patient which is tailor-made for the special tumor type.
- The immune system of the patient is used to dissolve the escape mechanism of the tumor and to strengthen the immune response of the diseased animals.
- No investments for the veterinarian are necessary, decentralized care (apart from centers offering chemotherapy or radiation therapy) at the location of the home veterinarian is possible.
- Neither the veterinarian and his team nor the patient owner and his family are exposed to bio-hazard caused by existing therapy options such as chemotherapy.
- The approach increases the quality of life for the patient from the start of the therapy, including the strengthening of his immune system.
Stage of Development:
Already on the market
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
The SME is looking for partners from veterinary centers, clinics and practices as well as contact to veterinary associations mainly in the UK but also from Austria, Spain, Singapore and the USA to further establish this therapy approach under various kinds of possible agreements. Mainly a commercial agreement with technical assistance or direct service agreements with single vets or clinics. Partners from other countries may be considered.

Also a Joint venture agreement could be possible to expand the lab facilities to UK.

Furthermore the company is interested in Research collaborations to further develop the technology to other treatment areas such as autoimmune diseases and regenerative applications.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French
German
Portuguese
Spanish

Dissemination

Restrict dissemination to specific countries:
Austria, France, Italy, Singapore, Spain, Switzerland, United Kingdom, United States

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001003 Citología, cancerología, oncología
07001009 Medicina veterinaria